Ensysce Biosciences receives Nasdaq delisting notice for equity deficiency below $2.5M

Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read

Key Changes

• high

  Company failed to meet Nasdaq's $2.5 million stockholders' equity requirement as of March 31, 2026, triggering formal delisting notice on May 21, 2026.

  Item 3.01 verify on EDGAR →
• high

  Ensysce must submit compliance plan by July 6, 2026 (45 days from notice). If accepted, could receive up to 180 days to regain compliance; if rejected, can appeal to Nasdaq Hearings Panel.

  Item 3.01 verify on EDGAR →
• high

  Company disclosed no assurance it can regain compliance, even if granted extension. Uncertainty exists around plan acceptance, appeal success, and ability to rebuild equity within deadline.

  Item 3.01 verify on EDGAR →